William Blair Analysts Increase Earnings Estimates for ADPT

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) – Research analysts at William Blair upped their FY2025 earnings per share (EPS) estimates for shares of Adaptive Biotechnologies in a report released on Wednesday, November 5th. William Blair analyst A. Brackmann now expects that the company will post earnings of ($0.49) per share for the year, up from their previous estimate of ($0.56). The consensus estimate for Adaptive Biotechnologies’ current full-year earnings is ($0.92) per share. William Blair also issued estimates for Adaptive Biotechnologies’ Q4 2025 earnings at ($0.18) EPS, Q1 2026 earnings at ($0.18) EPS, Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.12) EPS and FY2026 earnings at ($0.60) EPS.

Several other equities research analysts have also commented on ADPT. JPMorgan Chase & Co. boosted their target price on shares of Adaptive Biotechnologies from $17.00 to $20.00 and gave the stock an “overweight” rating in a research report on Thursday. Piper Sandler raised their price objective on shares of Adaptive Biotechnologies from $15.00 to $20.00 and gave the company an “overweight” rating in a research note on Wednesday, October 15th. TD Cowen boosted their price objective on shares of Adaptive Biotechnologies from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, August 6th. BTIG Research upped their target price on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Guggenheim assumed coverage on shares of Adaptive Biotechnologies in a research report on Tuesday, September 30th. They set a “buy” rating and a $20.00 price target for the company. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Adaptive Biotechnologies currently has an average rating of “Moderate Buy” and a consensus price target of $15.78.

Adaptive Biotechnologies Price Performance

Shares of ADPT stock opened at $14.79 on Monday. The business’s fifty day moving average price is $14.86 and its 200 day moving average price is $12.11. The firm has a market capitalization of $2.26 billion, a PE ratio of -18.04 and a beta of 2.09. Adaptive Biotechnologies has a 1-year low of $4.27 and a 1-year high of $17.89.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.01. Adaptive Biotechnologies had a negative return on equity of 60.93% and a negative net margin of 59.07%.The business had revenue of $93.97 million during the quarter, compared to analysts’ expectations of $58.76 million. During the same period last year, the firm earned ($0.22) EPS. The company’s quarterly revenue was up 102.4% compared to the same quarter last year.

Hedge Funds Weigh In On Adaptive Biotechnologies

A number of institutional investors have recently made changes to their positions in ADPT. Ameriprise Financial Inc. lifted its position in shares of Adaptive Biotechnologies by 801.6% in the first quarter. Ameriprise Financial Inc. now owns 6,642,476 shares of the company’s stock valued at $49,355,000 after acquiring an additional 5,905,756 shares in the last quarter. Braidwell LP acquired a new position in Adaptive Biotechnologies in the 1st quarter valued at about $35,692,000. Iron Triangle Partners LP acquired a new position in Adaptive Biotechnologies in the 1st quarter valued at about $15,856,000. Victory Capital Management Inc. lifted its holdings in Adaptive Biotechnologies by 9,892.2% in the 1st quarter. Victory Capital Management Inc. now owns 1,764,227 shares of the company’s stock valued at $13,108,000 after purchasing an additional 1,746,571 shares in the last quarter. Finally, Driehaus Capital Management LLC boosted its stake in shares of Adaptive Biotechnologies by 154.4% during the 1st quarter. Driehaus Capital Management LLC now owns 2,152,335 shares of the company’s stock worth $15,992,000 after purchasing an additional 1,306,164 shares during the last quarter. 99.17% of the stock is owned by institutional investors and hedge funds.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.